论文部分内容阅读
非酒精性脂肪性肝病(NAFLD)是与IR、肥胖和高脂血症密切相关的临床综合征。IR是T2DM和NAFLD共同的发病机制之一。一些降糖药物除降糖作用外还有控制体重、调节血脂和改善IR等特点,但有的本身具有药物性肝损害(DILI)。降糖药物是否对NAFLD产生影响尚无定论,本文就各类降糖药物和NAFLD的相关研究进展作一综述。
Non-alcoholic fatty liver disease (NAFLD) is a clinical syndrome closely related to IR, obesity and hyperlipidemia. IR is one of the common pathogenesis of T2DM and NAFLD. Some hypoglycemic drugs in addition to hypoglycemic effects also have weight control, lipid regulation and improve IR and other characteristics, but some itself has drug-induced liver damage (DILI). Whether or not hypoglycemic drugs have an effect on NAFLD is inconclusive. This review summarizes the progress of research on various types of hypoglycemic drugs and NAFLD.